Bids Are Invited For Price Registration, For A Period Of One Year, Which May Be Extended For The Same Period ... in Brazil

Work Detail

(L1) 6501.40712-Dabrafenib, 75 Mg, Capsule, Blister, Route Of Administration: Oral, Units. Size: Unit, (L2) 6501.19214-Fampridine, 10 Mg, Extended Release Tablet, Vial, (L3) 6501.31213-Golimumab, 50 Mg, Injectable Solution, Carpule, 0.5 Ml, Applicator Pen, Route Of Administration: Subcutaneous , (L4) 6501.22591-Icatibanto, 30 Mg, Prefilled Syringe, 3 Ml, (L5) 6501.93967-Inclisirana, 284Mg/1.5Ml, 10/21/2024, (L6) 6501.2844-Miglustat, 100 Mg, Gelatin Capsule Osa Dura, (L7) 6501.19219-Natalizumab, 300 Mg, Vial-Ampule, Route Of Administration: Intravenous, (L8) 6501.88130-Ofatumumab, 20Mg/0.4Ml, (L9) 6501.57874-Ribociclib, 200 Mg, Coated Tablet, (L10 65) 01.74175 -Romosozumab, 90 Mg/Ml, 1.17 Ml, (L11) 6501.54899-Tafamidis Meglumine, 20 Mg, Soft Capsule, (L12) 6501.93588-Tezepelumab, 210 Mg/ 1.91 Ml, (L13) Be Deruxtecana, Lyophilized Powder For Injectable Solution, Diluent, (L14) 6501.84839-Trifluridine + Tipiracil Hydrochloride, 15 Mg + 7.065 Mg, (L15) 6501.81734-Upadacitinib, 15 Mg, Coated Extended Release Tablet

Contact Information

Other Detail